BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31983177)

  • 1. Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial.
    Pongudom S; Phinyo P; Chinthammitr Y; Charoenprasert K; Kasyanan H; Wongyai K; Purattanamal J; Panoi N; Surawong A
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):147-155. PubMed ID: 31983177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial.
    Phinyo P; Patumanond J; Pongudom S
    BMC Res Notes; 2021 Jan; 14(1):3. PubMed ID: 33407868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review.
    Tandon N; Banavali S; Menon H; Gujral S; Kadam PA; Bakshi A
    Indian J Cancer; 2013; 50(2):154-8. PubMed ID: 23979209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL)].
    Yang H; Niu JH; Zhu CY; Zhang Q; Zhu HY; Yao ZL; Zhou MH; Wang QS; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):957-64. PubMed ID: 25130810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients.
    Berger E; Delpierre C; Despas F; Bertoli S; Bérard E; Bombarde O; Bories P; Sarry A; Laurent G; Récher C; Lamy S
    BMC Cancer; 2019 Sep; 19(1):883. PubMed ID: 31488077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
    Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
    Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 11. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
    Lao Z; Yiu R; Wong GC; Ho A
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia].
    Jehn U; Löwenberg B
    Onkologie; 1985 Apr; 8(2):97-8. PubMed ID: 3889758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
    Jehn U; Zittoun R; Löwenberg B
    Onkologie; 1985 Jun; 8(3):160-4. PubMed ID: 3895099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
    Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
    J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
    Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
    Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.